Cardiogenic shock after acute myocardial infarction. Causes, diagnosis, and treatment;Infarktbedingter kardiogener Schock: Ursache, Diagnose und Behandlung

Intensivmedizin und Notfallmedizin

Volumn 47, Issue 8, 2010, Pages 597-611

  Buerke, M ^a   Lemm, H ^a   Dietz, S ^a   Werdan, K ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Dobutamine; Myocardial infarction; Myocardial revascularization; Noradrenaline; Shock, cardiogenic

Indexed keywords

EID: 78149454641     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-010-0215-0     Document Type: Article

References (31)

1. Adams HA, Baumann G, Gansslen A et al (2001) Definition of shock types. Anasthesiol Intensivmed Notfallmed Schmerzther 36(Suppl 2): S140-S143.
2. Alexander JH, Reynolds HR, Stebbins AL et al (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297: 1657-1666.
3. Chen EW, Canto JG, Parsons LS et al (2003) Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 108: 951-957.
4. Christoph A, Prondzinsky R, Russ M et al (2008) Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care 10: 49-57.
5. Cotter G, Kaluski E, Milo O et al (2003) LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 24: 1287-1295.
6. Cotter G, Williams Sg, Vered Z et al (2003) Role of cardiac power in heart failure. Curr Opin Cardiol 18: 215-222.
7. Cuffe MS, Califf RM, Adams KF Jr et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287: 1541-1547.
8. De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362: 779-789.
9. Delle Karth G, Buberl A, Geppert A et al (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47: 1251-1256.
10. Field S, Kelly SM, Macklem PT (1982) The oxygen cost of breathing in patients with cardiorespiratory disease. Am Rev Respir Dis 126: 9-13.
11. Friedrich JO, Adhikari N, Herridge MS et al (2005) Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142: 510-524.
12. Fuhrmann JT, Schmeisser A, Schulze MR et al (2008) Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 36: 2257-2266.
13. Geppert A, Steiner A, Zorn G et al (2002) Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 30: 1987-1994.
14. Heer T, Zeymer U, Juenger C et al (2006) Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice. Heart 92: 1484-1489.
15. Hochman JS, Boland J, Sleeper LA et al. (1995) Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an international registry. SHOCK Registry Investigators. Circulation 91: 873-881.
16. Hochman JS, Buller CE, Sleeper LA et al (2000) Cardiogenic shock complicating acute myocardial infarction - etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 36: 1063-1070.
17. Hochman JS, Sleeper LA, Webb JG et al (2006) Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 295: 2511-2515.
18. Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341: 625-634.
19. Jolly S, Newton G, Horlick E et al (2005) Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 96: 1617-1620.
20. Lindholm Mg, Kober L, Boesgaard S et al (2003) Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. Eur Heart J 24: 258-265.
21. Metra M, Nodari S, D'aloia A et al (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40: 1248-1258.
22. Prondzinsky R, Lemm H, Swyter M et al (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 38: 152-160.
23. Rassin M, Sruyah R, Kahalon A et al (2007) Between the fixed and the changing: examining and comparing reliability and validity of 3 sedation-agitation measuring scales. Dimens Crit Care Nurs 26: 76-82.
24. Russ MA, Prondzinsky R, Carter JM et al (2009) Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med 37: 3017-3023.
25. Russ MA, Prondzinsky R, Christoph A et al (2007) Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35: 2732-2739.
26. Sjauw KD, Engstrom AE, Vis MM et al (2009) A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: Should we change the guidelines? Eur Heart J 30: 459-468.
27. Slater J, Brown RJ, Antonelli TA et al (2000) Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 36: 1117-1122.
28. Webb JG, Lowe AM, Sanborn TA et al (2003) Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 42: 1380-1386.
29. Webb JG, Sleeper LA, Buller CE et al (2000) Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 36: 1084-1090.
30. White HD, Assmann SF, Sanborn TA et al (2005) Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 112: 1992-2001.
31. Zion MM, Balkin J, Rosenmann D et al (1990) Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5, 841 patients in the SPRINT registry. SPRINT Study Group. Chest 98: 1331-1335.